Page results
-
UCLH has recruited the first participant to an international trial in frontotemporal dementia (FTD), one of the most common causes of early-onset dementia.
-
“Vaccines do not kill, the virus does”: that was the message from local leaders from a variety of different faiths during an event at the newly opened vaccination centre at the Business Design Centre in Islington.
-
Patient information for patients having a thymectomy procedure.
-
Swapping the standard blue curtains for sunny yellow ones has made our postnatal ward feel brighter and less clinical.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
Information for patients having a surgery via median sternotomy.
-
Elderly patients suffering the most common type of heart attack may benefit from more invasive treatment, new research involving UCLH has shown.
-
Information for patients having a mediastinoscopy / mediastinotomy procedure.
-
A pioneering breast cancer therapy developed by UCLH and UCL, which requires just one shot of radiotherapy rather than conventional weeks-long treatment, has proven to be as effective for most women in treating the disease.
-
The National Hospital for Neurology and Neurosurgery (NHNN), part of UCLH NHS Foundation Trust, has been reaccredited under the prestigious Royal College of Anaesthetists (RCoA) Anaesthesia Clinical Services Accreditation (ACSA) demonstrating the hospital anaesthetists’ commitment to patient safety and excellence of care.
File results
-
FOI/2022/0200 - IT budget/ chatbots
-
FOI/2022/0205 - Spending on communication activities
-
FOI/2022/206 - Rates for Bonham Carter House 52-54 Gower Street
-
FOI/2022/0207 - Patient treatment with Nivolumab
-
FOI/2022/0209 - Patient tracking list or waiting lists
-
FOI/2022/0211 - Enteral feeding machine mechanical insufflator
-
FOI/2022/0212 - Clotting disorders medication
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications